Table 1 Characteristics of all patients and patients with different BRCA1 status
All patientsd (n = 485) | BRCA1-non-alteration (n = 127) | gBRCA1m (n = 105) | sBRCA1m (n = 21) | Tumor BRCA1-PM (n = 146) | P-valuee | |
|---|---|---|---|---|---|---|
Age at diagnosis, median (Q1–Q3), years | 35 (32–38) | 35 (32–38) | 35 (32–37) | 35 (33–37) | 35 (33–38) | 0.545 |
sTILs, median (Q1–Q3), % | 25 (5, 70) | 23 (5, 65) | 20 (10, 75) | 27 (10, 65) | 40 (5, 70) | 0.448 |
Missinga | 4 | 1 | 0 | 0 | 1 | |
Tumor size, no. (%) | ||||||
≤ 20 mm | 285 (59.0) | 69 (54.8) | 66 (63.5) | 9 (42.9) | 87 (59.6) | 0.268 |
> 20 mm | 198 (41.0) | 57 (45.2) | 38 (36.5) | 12 (57.1) | 59 (40.4) | |
Missinga | 2 | 1 | 1 | 0 | 0 | |
Tumor grade, no. (%) | ||||||
Grade 1 or 2 | 70 (14.4) | 17 (13.4) | 12 (11.4) | 2 (9.5) | 14 (9.6) | 0.795 |
Grade 3 | 415 (85.6) | 110 (86.6) | 93 (88.6) | 19 (90.5) | 132 (90.4) | |
Histological subtype, no. (%) | ||||||
Carcinoma no special type | 445 (91.8) | 113 (89.0) | 97 (92.4) | 21 (100.0) | 135 (92.5) | 0.501 |
Metaplastic carcinoma | 27 (5.6) | 9 (7.1) | 5 (4.8) | 0 (0.0) | 10 (6.8) | |
Other subtypes | 13 (2.7) | 5 (3.9) | 3 (2.9) | 0 (0.0) | 1 (0.7) | |
Lymphovascular invasion, no. (%) | ||||||
No | 429 (88.5) | 110 (86.6) | 94 (89.5) | 17 (81.0) | 131 (89.7) | 0.550 |
Yes | 56 (11.5) | 17 (13.4) | 11 (10.5) | 4 (19.0) | 15 (10.3) | |
BRCA1-like tumor, no. (%) | ||||||
Non-BRCA1-like | 48 (13.6) | 19 (19.2) | 11 (12.9) | 3 (17.6) | 9 (7.4) | 0.051 |
BRCA1-like | 304 (86.4) | 80 (80.8) | 74 (87.1) | 14 (82.4) | 113 (92.6) | |
Missinga | 133 | 28 | 20 | 4 | 24 | |
BRCA1 mRNA expression, median (Q1–Q3), normalized counts | 864.54 (273.81–1342.70) | 1273.55 (905.61–1745.19) | 1165.90 (864.00–1555.9) | 911.90 (725.80–1366.7) | 214.30 (132.26–320.54) | < 0.001 |
Missinga | 133 | 23 | 19 | 5 | 36 | |
Surgery type, no. (%) | ||||||
Lumpectomy | 324 (66.8) | 86 (67.7) | 62 (59.0) | 12 (57.1) | 102 (69.9) | 0.333 |
Mastectomy | 152 (31.3) | 38 (29.9) | 39 (37.1) | 9 (42.9) | 43 (29.5) | |
Surgery not specified | 9 (1.9) | 3 (2.4) | 4 (3.8) | 0 (0.0) | 1 (0.7) | |
Radiotherapy, no. (%) | ||||||
No radiotherapy | 141 (29.1) | 36 (28.3) | 35 (33.3) | 8 (38.1) | 39 (26.7) | 0.550 |
Radiotherapy | 344 (70.9) | 91 (71.7) | 70 (66.7) | 13 (61.9) | 107 (73.3) | |
Events of interest during 15-year follow-upb, no. (%) | ||||||
Death due to any cause | 137 (28.5) | 37 (29.8) | 40 (38.1) | 7 (33.3) | 32 (22.2) | NA |
First distant recurrence | 83 (17.3) | 24 (19.4) | 20 (19.0) | 7 (33.3) | 21 (14.6) | NA |
Death without distant recurrence or second primary tumors | 34 (7.1) | 8 (6.5) | 8 (7.6) | 1 (4.8) | 10 (6.9) | NA |
First second primary tumors | 85 (17.7) | 17 (13.7) | 48 (45.7) | 1 (4.8) | 9 (6.2) | NA |
The location of the first and second primary tumorsb, no. (%) | ||||||
Contralateral breast | 64 (75.3) | 13 (76.5) | 40 (83.3) | 1 (100) | 5 (55.6) | NA |
Ipsilateral breast | 5 (5.9) | 1 (5.9) | 1 (2.1) | 0 (0) | 2 (22.2) | |
Ovary | 8 (9.4) | 1 (5.9) | 5 (10.4) | 0 (0) | 1 (11.1) | |
Other locationsc | 8 (9.4) | 2 (11.8) | 2 (4.2) | 0 (0) | 1 (11.1) | |
Lost to follow-up, no. (%) | 8 (1.7) | 1 (0.8) | 1 (1.0) | 1 (4.8) | 3 (2.1) | NA |